GlassScriptPhysician profile
Cathy S Berkovitz
NPI 1184046153
$6,225.68
in general payments reported to CMS, 2019-2025
36 companies · $725 in 2025
The $725 reported for 2025 was more than what 98% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $810 · 2022: $1,421 · 2023: $2,322 · 2024: $947 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,994 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,994.05 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $457.85 | 2022-2023 | Dupixent, Evkeeza |
| Edwards Lifesciences Corporation | $398.74 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novo Nordisk INC | $357.43 | 2021-2024 | |
| Abbvie INC. | $329.16 | 2021-2024 | |
| Hologic Sales and Service, LLC | $274.28 | 2023 | Aptima |
| Teva Pharmaceuticals USA, INC. | $260.73 | 2024-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $254.00 | 2023-2024 | Invega Sustenna, Invega Trinza, Xarelto |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $249.49 | 2023 | Jynarque |
| Amgen INC. | $246.01 | 2024-2025 | Repatha |
| Ultragenyx Pharmaceutical INC. | $243.26 | 2022-2025 | Dojolvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.30 | 2021-2023 | |
| Sage Therapeutics, LLC | $229.44 | 2023 | |
| Sanofi-Aventis U.S. LLC | $139.42 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.91 | 2021 | |
| Alnylam Pharmaceuticals INC. | $127.89 | 2024 | Onpattro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125.92 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $125.27 | 2023 | |
| Shield Therapeutics INC | $125.01 | 2022 | |
| Neurelis, INC. | $125.00 | 2023 | Valtoco |
| Amag Pharmaceuticals, INC. | $124.98 | 2021 | |
| Lundbeck LLC | $124.73 | 2022 | |
| Lucid Diagnostics INC. | $124.59 | 2022 | |
| Sk Life Science, INC. | $123.86 | 2022 | |
| Genentech USA, INC. | $122.90 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $121.82 | 2023 | Relyvrio |
| Argenx US, INC. | $120.60 | 2024 | Vyvgart |
| Otsuka America Pharmaceutical, INC. | $120.39 | 2023 | Rexulti |
| Stryker Corporation | $108.93 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Idorsia Pharmaceuticals US INC | $108.21 | 2023 | Quviviq |
| Emd Serono, INC. | $101.04 | 2025 | |
| Gilead Sciences, INC. | $90.40 | 2022 | |
| Gen-Probe Sales & Service, INC. | $86.47 | 2021 | |
| Janssen Scientific Affairs, LLC | $85.12 | 2022 | |
| Abbott Laboratories | $77.60 | 2022 | |
| Scynexis, INC. | $77.38 | 2022 | |
| Fresenius Kabi USA, LLC | $66.55 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Berkovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.